Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

The FDA has approved a mu-opioid receptor antagonist for the treatment of opioid-induced constipation (OIC). Naloxegol is a pegylated derivative of naloxone which acts on peripheral (e.g., gut) mu-receptors. It is marketed by AstraZeneca Pharmaceuticals as Movantik.

Naloxegol Tablets (Movantik ¢â )